Universal Biosensors Announces FY2015 Results Showing Strong Revenue Growth and Positive Operating Cash

17th February 2016, ASX Announcement

Highlight of FY 2015

• Revenue from Quarterly Service Fees – generated by sales of OneTouch Verio blood glucose test strips by LifeScan – up 99% to $12.8 million in FY 2015 from $6.4 million in FY2014
• Revenue from supply of test strips for the Siemens Xprecia Stride Coagulation Analyzer reach $1.3M in first full year of commercial sales
• Net development expense (after R&D tax rebate) increased to $10.5 million in FY2015, from $7.2 million in FY2014
• Net loss of $6.6 million in FY2015, an improvement on the net loss of $9.3 million in FY2014
• Positive operating cash flow of $1.8 million, up from negative $(5.4) million in FY2014
• Closing cash balance at 31 December 2015 of $14.4 million

Universal Biosensors (ASX:UBI) today released its full year results for FY2015. Total revenue increased 76% to $16.8 million in FY2015, from $9.5 million in FY2014. In FY2015, the key revenue contributor was the Quarterly Service Fees, generated by sales of OneTouch Verio blood glucose test strips by LifeScan, which doubled to $12.8 million in FY2015 (up from $6.4 million in FY 2014). In addition, UBI generated $2 million in revenue from milestone payments in FY2015, up 12% on FY2014.

To read the full announcement, please click here.

To view the investor presentation, please click here.

Universal Biosensors will be hosting an investor webcast to present the FY 2015 results on Friday, 19 February at 11am AEDT. The call will be hosted by Universal Biosensors Chief Executive Officer, Paul Wright.
Shareholders are invited to listen to a webcast of the full year results via the following link:
http://webcasting.brrmedia.com/broadcast/56b823c9c23d9659538e181f

To find out more about the investor webcast, please click here.